Pernicious Anemia Diagnosis and Treatment Market to reach $2,883.0 million by 2035

Pernicious anemia diagnosis and treatment market was valued at $1,428.1 million in 2025 and is projected to reach $2,883.0 million by 2035, growing at a CAGR of 6.8% during the forecast period 2026-2035, according to a new report by Orion Market Research. The Pernicious Anemia Diagnosis and Treatment Market is being driven by multiple factors, including increasing awareness of vitamin B12 deficiency, the rising prevalence of the condition, and the need for lifelong management of affected patients. Among these, technological advancements are emerging as a major growth driver. AI-driven diagnostics enable earlier detection, while telehealth and remote monitoring improve ongoing care and treatment adherence, expanding access and boosting demand for diagnostics and therapies.

Browse the full report description of “Pernicious Anemia Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Complete Blood Count Test, Vitamin B-12 Deficiency Test, Biopsy, and Intrinsic Factor Deficiency Test), By Treatment (Vitamin B-12 Injections, Vitamin B-12 Pills, and Other), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/pernicious-anemia-diagnosis-and-treatment-market

AI & Telehealth Driving Pernicious Anemia Market Growth

Technological advancements, particularly the integration of AI and telehealth, are significantly accelerating demand in the Pernicious Anemia Diagnosis and Treatment Market by improving early detection, access to care, and long-term disease management. As per Pernicious Anemia society 37% of patients wait five years or more for a diagnosis, highlighting the urgent need for faster and more accurate detection methods.

AI-driven diagnostics are reshaping the front end of the care pathway for the Pernicious Anemia Diagnosis and Treatment market. Advanced algorithms can now analyze routine Complete Blood Count (CBC) data at scale to detect subtle hematological abnormalities such as macrocytosis or elevated Mean Corpuscular Volume (MCV), which are early indicators of vitamin B12 deficiency. This enables clinicians to identify high-risk patients earlier and trigger confirmatory testing (intrinsic factor antibodies, serum B12 levels) well before severe neurological or hematological complications develop. An earlier diagnosis means more patients are identified sooner, allowing treatment to begin earlier and increasing the number of people receiving ongoing care. This directly boosts demand for diagnostic tests and long-term treatment options in the pernicious anemia market.

At the same time, telehealth and remote monitoring platforms are transforming disease management, which is critical for pernicious anemia as it requires lifelong vitamin B12 supplementation and regular follow-up. Digital health tools allow physicians to remotely track patient compliance, symptom progression, and laboratory markers, reducing the need for frequent in-person visits. This is especially impactful in rural and underserved regions where access to hematology specialists is limited. By lowering barriers to ongoing care and improving adherence, telehealth expands treatment continuity and patient retention, ultimately supporting sustained growth in both diagnostic services and therapeutic demand across the market.

So, technological innovations like AI-driven diagnostics and telehealth are transforming how pernicious anemia is detected and managed. By catching subtle signs of vitamin B12 deficiency earlier and making ongoing care easier even for patients in remote areas, these tools are helping more people get diagnosed and treated on time. This not only improves patient outcomes but is also fueling steady growth in demand for diagnostic tests and long-term treatments in the pernicious anemia market.

Key Business Development in Pernicious Anemia Diagnosis and Treatment Market

• In February 2024, Lupin Limited launched a Cyanocobalamin Nasal Spray (500?mcg) in the U.S., approved by the FDA for long-term vitamin B12 therapy in patients with pernicious anemia. This non-invasive alternative to injections improves patient compliance and is expected to increase demand for B12 treatment in the market.

• In 2024, bioMérieux received CE?marking for its VIDAS VITAMIN B12 TOTAL test, an automated assay that measures total vitamin B12 in serum or plasma. This test enables laboratories to assess B12 status more efficiently and reliably, supporting the diagnosis of B12 deficiency and pernicious anemia, with commercial rollout continuing into 2025.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Diagnosis
• Treatment

• Competitive Landscape – Abbott Laboratories, Danaher Corp. (Beckman Coulter), F. Hoffmann-La Roche Ltd., Siemens Healthineers AG and Sysmex Corp.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pernicious Anemia Diagnosis and Treatment Market Report Segment

By Diagnosis

• Complete Blood Count Test
• Vitamin B-12 Deficiency Test
• Biopsy
• Intrinsic Factor Deficiency Test

By Treatment

• Vitamin B-12 Injections
• Vitamin B-12 Pills
• Other (Spray)

Global Pernicious Anemia Diagnosis and Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pernicious-anemia-diagnosis-and-treatment-market